QuidelOrtho Co. (NASDAQ:QDEL) Shares Sold by Signaturefd LLC

Signaturefd LLC decreased its position in QuidelOrtho Co. (NASDAQ:QDEL) by 44.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 864 shares of the company’s stock after selling 684 shares during the quarter. Signaturefd LLC’s holdings in QuidelOrtho were worth $38,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its stake in shares of QuidelOrtho by 188.0% in the fourth quarter. Blue Trust Inc. now owns 1,293 shares of the company’s stock valued at $58,000 after purchasing an additional 844 shares during the period. Spire Wealth Management purchased a new position in QuidelOrtho in the 4th quarter valued at approximately $74,000. KBC Group NV boosted its position in QuidelOrtho by 122.9% in the 4th quarter. KBC Group NV now owns 3,437 shares of the company’s stock valued at $153,000 after buying an additional 1,895 shares during the period. Captrust Financial Advisors acquired a new position in shares of QuidelOrtho in the third quarter worth $238,000. Finally, CIBC Asset Management Inc increased its position in shares of QuidelOrtho by 14.2% during the fourth quarter. CIBC Asset Management Inc now owns 6,564 shares of the company’s stock worth $292,000 after acquiring an additional 816 shares during the period. 99.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on QDEL. Royal Bank of Canada decreased their target price on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a report on Thursday, February 13th. Citigroup raised QuidelOrtho from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $44.00 to $50.00 in a research report on Wednesday, December 11th. Jefferies Financial Group assumed coverage on shares of QuidelOrtho in a report on Tuesday, December 10th. They issued a “hold” rating and a $43.00 target price on the stock. UBS Group boosted their price target on shares of QuidelOrtho from $43.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th. Finally, StockNews.com lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, QuidelOrtho presently has an average rating of “Hold” and an average price target of $51.20.

QuidelOrtho Trading Down 3.2 %

NASDAQ QDEL opened at $35.35 on Wednesday. QuidelOrtho Co. has a 12 month low of $29.74 and a 12 month high of $49.45. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -1.17 and a beta of 0.10. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 0.69. The firm’s fifty day moving average price is $40.50 and its 200 day moving average price is $41.59.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. On average, sell-side analysts expect that QuidelOrtho Co. will post 2.3 earnings per share for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.